CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | Jung Cassie Chief Operating Officer | Grant or award | +80,000 | 320,771 | ||
| 2026-03-09 | Jung Cassie Chief Operating Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +42,500 | 42,500 | ||
| 2026-03-09 | Davis Matthew W. Chief Development Officer | Grant or award | +50,000 | 100,000 | ||
| 2026-03-09 | Davis Matthew W. Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-03-09 | Greenhawt Matthew J. Chief Medical Officer | Grant or award | +75,000 | 75,000 | ||
| 2026-03-09 | Greenhawt Matthew J. Chief Medical Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | $4.29 | $215K | 50,000 |
| 2025-12-04 | Boyd Peter E. Chief People Officer | Grant or award | +20,000 | 288,323 | ||
| 2025-12-02 | Cioffi Melina SVP, Regulatory Affairs | Shares withheld for taxes | −2,083 | $5.93 | $12K | 200,178 |
| 2025-11-10 | Davis Matthew W. Chief Development Officer | Grant or award | +50,000 | 50,000 | ||
| 2025-11-10 | Davis Matthew W. Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-10-15 | Jung Cassie Chief Operating Officer | Option exercise 10b5-1 | +25,000 | $3.10 | $78K | 308,346 |
| 2025-10-15 | Jung Cassie Chief Operating Officer | Sale 10b5-1 | −67,575 | $7.01 | $474K | 240,771 |
| 2025-10-15 | Jung Cassie Chief Operating Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −25,000 | 0 | ||
| 2025-10-15 | Kraus Carl N Chief Medical Officer | Sale 10b5-1 | −20,272 | $7.00 | $142K | 282,475 |
| 2025-10-15 | Boyd Peter E. See Remarks | Sale 10b5-1 | −10,000 | $7.00 | $70K | 268,323 |
| 2025-09-26 | Barber Daniel President and CEO | Sale 10b5-1 | −91,343 | $6.03 | $551K | 923,430 |
| 2025-09-26 | Boyd Peter E. See Remarks | Sale 10b5-1 | −10,000 | $6.30 | $63K | 278,323 |
| 2025-09-19 | Barber Daniel President and CEO | Sale 10b5-1 | −400 | $6.00 | $2K | 1,014,773 |
| 2025-09-05 | Boyd Peter E. See Remarks | Sale 10b5-1 | −15,000 | $5.30 | $80K | 288,323 |
| 2025-09-04 | Jung Cassie Chief Operating Officer | Option exercise 10b5-1 | +25,000 | $3.15 | $79K | 320,526 |
Page 4 of 24 · 462 trades